AstraZeneca unveils successes in treatment of lung cancer
Targeted drug osimertinib (Tagrisso) is showing strong results for certain genetic subtypes of non-small cell lung cancer, especially when used early or in combination with chemotherapy, offering some patients years of relatively normal life even at stage 4. Commenters weigh these gains against side effects, high costs, and sobering statistics on overall cancer drug efficacy, while sharing experiences with screening, staging, and how modern therapies and clinical trials are slowly changing what was once an almost certain death sentence.
Drug overview and approvals
- Discussion centers on osimertinib (Tagrisso), an EGFR tyrosine kinase inhibitor for certain non‑small cell lung cancers.
- Works best when cancers have specific mutations (e.g., T790M, L858R; other EGFR variants mentioned) and often in earlier or molecularly defined stages.
- Initially approved mid‑2010s for specific late-stage EGFR-mutant disease; approvals later expanded to first-line and adjuvant (early-stage) settings.
Effectiveness, staging, and resistance
- “Early stage” in the thread generally means in situ or localized (not yet spread beyond primary organ).
- Several comments highlight dramatic responses: tumor shrinkage, long progression‑free survival, and people alive years beyond prior prognoses.
- Others note resistance typically develops within about 10 months for some patients, or after ~16 months on related targeted drugs, as tumors mutate around the therapy.
Side effects and treatment burden
- Commonly cited side effects: diarrhea, rashes, dry/itchy skin, nail infections, blood count drops, and mouth sores.
- Compared with traditional chemo, many posters describe side effects as “mild” or manageable and strongly preferable to standard regimens.
- Some discuss combination regimens (osimertinib + chemo) that are harsher short‑term but improve progression‑free survival.
Real-world experiences
- Multiple accounts of stage 4 lung cancer patients alive and functional due to osimertinib or similar targeted drugs; in some cases, disease has regressed significantly.
- Others describe relatives who died rapidly or after prolonged suffering, underscoring how aggressive and variable lung cancer can be.
- A 31‑year‑old patient reports being on osimertinib with an estimated ~2‑year life expectancy but relatively normal daily life.
Screening, other treatments, and data resources
- Strong emphasis on early detection for high‑risk groups (especially long‑term smokers) via low‑dose CT; many eligible people reportedly never get screened.
- Mentions of Cuban CimaVax lung cancer vaccine, now in US trials, and of immunotherapies (e.g., Keytruda) dramatically extending survival for some cancers.
- References to NCCN guidelines and clinicaltrials.gov as central but complex sources of treatment and trial information; some work aims to translate these into patient‑friendly tools.
Costs, policy, and ethics
- Drug cost cited around $10k/month without good insurance; some patients must keep working to maintain coverage.
- Debate over overall cancer‑drug gains: median life extension across many drugs may be small, but distributions are skewed; a minority of patients gain many high‑quality years.
- Emotional discussion of end‑of‑life suffering, palliative care, and euthanasia laws; encouragement for life insurance and advance planning.